tert-butyl 4-neopentylpiperazine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-neopentylpiperazine-1-carboxylate
• 英文别名: 1-[4-(2,2-Dimethylpropyl)piperazin-1-yl]-2,2-dimethylpropan-1-one；1-[4-(2,2-dimethylpropyl)piperazin-1-yl]-2,2-dimethylpropan-1-one
• 化学式: C₁₄H₂₈N₂O
• 分子量: 240.389
• InChiKey: DGCDARATKMRBOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  1-三甲基乙酰基哌嗪	2,2-dimethyl-1-(piperazin-1-yl)propan-1-one	155295-47-9	C9H18N2O	170.255

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  1-新戊基哌嗪	1-(2,2-dimethyl-propyl)-piperazine	57184-50-6	C9H20N2	156.271

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-neopentylpiperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以60%的产率得到1-新戊基哌嗪
  参考文献：
  名称：

  Novel Vanilloid Receptor-1 Antagonists:  3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties

  摘要：

  Based on the previously reported clinical candidate, AMG 517 (compound 1), a series of related piperazinylpyrimidine analogues were synthesized and evaluated as antagonists of the vanilloid 1 receptor (VR1 or TRPV1). Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>= 200 mu g/mL in 0.01 N HCl) and a reduced half-life (rat t(1/2) = 3.8 h, dog t(1/2) = 2.7 h, monkey t(1/2) = 3.2 h) as compared to AMG 517. In addition, compound 16p was shown to be efficacious at blocking a TRPV1-mediated physiological response in vivo (ED50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch model in rats) and was also effective at reducing thermal hyperalgesia induced by complete Freund's adjuvant in rats (MED = 1 mg/kg, p.o). Based on its improved overall profile, compound 16p (AMG 628) was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.

  DOI：

  10.1021/jm070191h
• 作为产物：
  描述：

  特戊醛 、 1-三甲基乙酰基哌嗪 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 1.83h， 以100%的产率得到tert-butyl 4-neopentylpiperazine-1-carboxylate
  参考文献：
  名称：

  Novel Vanilloid Receptor-1 Antagonists:  3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties

  摘要：

  Based on the previously reported clinical candidate, AMG 517 (compound 1), a series of related piperazinylpyrimidine analogues were synthesized and evaluated as antagonists of the vanilloid 1 receptor (VR1 or TRPV1). Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>= 200 mu g/mL in 0.01 N HCl) and a reduced half-life (rat t(1/2) = 3.8 h, dog t(1/2) = 2.7 h, monkey t(1/2) = 3.2 h) as compared to AMG 517. In addition, compound 16p was shown to be efficacious at blocking a TRPV1-mediated physiological response in vivo (ED50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch model in rats) and was also effective at reducing thermal hyperalgesia induced by complete Freund's adjuvant in rats (MED = 1 mg/kg, p.o). Based on its improved overall profile, compound 16p (AMG 628) was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.

  DOI：

  10.1021/jm070191h

文献信息

• BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY
  申请人：Nurix Therapeutics, Inc.

  公开号：US20210198280A1

  公开（公告）日：2021-07-01

  This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
• Novel Vanilloid Receptor-1 Antagonists:  3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties
  作者：Hui-Ling Wang、Jodie Katon、Chenera Balan、Anthony W. Bannon、Charles Bernard、Elizabeth M. Doherty、Celia Dominguez、Narender R. Gavva、Vijay Gore、Vu Ma、Nobuko Nishimura、Sekhar Surapaneni、Phi Tang、Rami Tamir、Oliver Thiel、James J. S. Treanor、Mark H. Norman

  DOI：10.1021/jm070191h

  日期：2007.7.1

  Based on the previously reported clinical candidate, AMG 517 (compound 1), a series of related piperazinylpyrimidine analogues were synthesized and evaluated as antagonists of the vanilloid 1 receptor (VR1 or TRPV1). Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>= 200 mu g/mL in 0.01 N HCl) and a reduced half-life (rat t(1/2) = 3.8 h, dog t(1/2) = 2.7 h, monkey t(1/2) = 3.2 h) as compared to AMG 517. In addition, compound 16p was shown to be efficacious at blocking a TRPV1-mediated physiological response in vivo (ED50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch model in rats) and was also effective at reducing thermal hyperalgesia induced by complete Freund's adjuvant in rats (MED = 1 mg/kg, p.o). Based on its improved overall profile, compound 16p (AMG 628) was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.